Cabaletta Bio

General Information


We are a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Our lead CAAR T cell product candidate was designed based on chimeric antigen receptor, or CAR, T cell technology that has been successfully developed and is marketed for the treatment of B cell cancers.

Employees: 20
Founded: 2017
Contact Information
Address 2929 Arch Street, Suite 600, Philadelphia, PA 19104, US
Phone Number (267) 759-3100
Web Address
View Prospectus: Cabaletta Bio
Financial Information
Market Cap $259.1mil
Revenues $0 mil (last 12 months)
Net Income $-23.4 mil (last 12 months)
IPO Profile
Symbol CABA
Exchange NASDAQ
Shares (millions): 6.8
Price range $11.00 - $11.00
Est. $ Volume $74.8 mil
Manager / Joint Managers Morgan Stanley/ Cowen and Company/ Evercore
CO-Managers -
Expected To Trade: 10/25/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change